Arman Mashayekhi, MD
Ophthalmology · Jacksonville, FLNPI 1275860140
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,000 of the $4,189 with a category attached, or 95.5%. Carl Zeiss Meditec, Inc. accounts for 95.5% of it on its own, with 4 other manufacturers making up the rest. Reporting peaked in 2020 at $4,000 and has fallen 98.9% since, to $43 in 2025.
Across 5 payments — averaging $837.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Carl Zeiss Meditec, Inc.$4K
- Amgen$107
- AstraZeneca$43
- Abbott$25
- Apellis Pharmaceuticals, Inc.$14
What the payments were for
- Consulting fees$4,00095%
- Food & beverage$1463%
- Education$431%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Carl Zeiss Meditec, Inc. | 1 | $4,000 |
| Amgen | 1 | $107 |
| AstraZeneca | 1 | $43 |
| Abbott | 1 | $25 |
| Apellis Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,189 in reported general payments places this provider in the 70th percentile of 1,405 ophthalmology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 12 | $8,354 |
| Prednisolone Acetate | 74 | $1,922 |
| Latanoprost | 40 | $784 |
| Timolol Maleate | 29 | $319 |
| Atropine Sulfate | 13 | $310 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 16 | $208 |
| Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim | 25 | $173 |
| Prednisone | 12 | $138 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Jacksonville
- Syril DorairajJacksonville$432K
- Frank BowdenJacksonville$169K
- David KostickJacksonville$108K
- Cathleen McCabeBradenton$2M
- Daniel KiernanSarasota$1.7M
- David EichenbaumSt Petersburg$1.7M
- Mark MilnerPalm Beach Gardens$1.2M
- Neel DesaiLargo$1M
- Jorge FortunPalm Beach Gardens$798K
- Courtney BoveeTampa$796K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.